LYCOS RETRIEVER 
Pharmaceuticals: Drugs
built 605 days ago
GAITHERSBURG, MD, March 16, 2004 /PRNewswire/ -- Panacos Pharmaceuticals, Inc. today announced that it has begun a Phase 1 clinical trial of its small molecule HIV drug candidate PA-457. PA-457 has a different mechanism of action than approved HIV drugs and has potent activity against HIV strains resistant to current therapies, including inhibitors of reverse transcriptase and viral protease. In the Phase 1 trial, PA-457 is being administered orally to uninfected, healthy volunteers to evaluate the compound's safety and pharmacokinetics
Source:
Pharmaceuticals developed by biotechnological processes often must be injected in a physician's office rather than be delivered in the form of a capsule taken orally. Medicare payments for these drugs are usually made through Medicare Part B (physician office) rather than Part D (prescription drug plan).
Source:
In this section, you will find comprehensive information about drug benefit programs, how federal, provincial and territorial governments cooperate on pharmaceuticals management, and information on pharmaceutical costs and pricing and optimal drug therapy. You will ... be able to obtain access to key acts and regulations and pertinent reports.
Source:
MORE ABOUT
Drugs